Emergent Biosolutions
EBS
134 hedge funds and large institutions have $101M invested in Emergent Biosolutions in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 46 closing their positions.
1.74% more ownership
Funds ownership: 79.49% → 81.22% (+1.7%)
5% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 44
15% less call options, than puts
Call options by funds: $443K | Put options by funds: $520K
17% less funds holding
Funds holding: 162 → 134 (-28)
28% less capital invested
Capital invested by funds: $141M → $101M (-$39.7M)
59% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.37M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$3.09M |
| 3 |
BlackRock
New York
|
+$2.26M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.53M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.65M |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$1.84M |
| 4 |
Squarepoint
New York
|
-$1.19M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$936K |
EBS Hedge Fund Activity: Q4 2023 in Review
134 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2023, worth a combined $101M — down 28% from $141M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of EBS and 19 opened new positions — a net loss of 27 holders — while 44 trimmed existing stakes and 46 added.
The largest buyer was Morgan Stanley, adding an estimated $4.37M. The largest seller was Millennium Management, cutting an estimated $3.69M.
- 134 institutional investors held Emergent Biosolutions (EBS) as of Q4 2023, down from 162 in Q3 2023.
- Funds reported $101M of Emergent Biosolutions stock for Q4 2023, down 28% quarter-over-quarter.
- 19 funds opened new Emergent Biosolutions positions in Q4 2023 and 46 closed out, a net change of -27 holders.
- The largest Emergent Biosolutions buyer in Q4 2023 was Morgan Stanley, an estimated $4.37M added.
- The largest Emergent Biosolutions seller in Q4 2023 was Millennium Management, an estimated $3.69M sold.
Based on aggregated 13F filings for Q4 2023.